Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions.  Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.  Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.

Despite the subpar data regarding 1404 and PyL, Progenics Pharmaceuticals is undergoing strong fundamental improvement.

Progenics: Placing Catalysts Into Context

Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Progenics (PGNX) Q1 Earnings Expected to Decline

I have been hesitant about buying into Progenics Pharmaceuticals due to my insufficient knowledge about the advancements of radiopharmaceuticals in the oncology arena.

Progenics: Why I Finally Decided To Buy

Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q4 2018 Results - Earnings Call Transcript

News for Progenics Pharmaceuticals Stock (PGNX)